4876-60-2 Usage
Description
1,4'-Bipiperidine dihydrochloride is a chemical compound that belongs to the class of piperidine derivatives. It is commonly used in organic synthesis and in the pharmaceutical industry for the production of various drugs, including antihistamines and antipsychotics. As a dihydrochloride salt, it exists as a white crystalline solid that is soluble in water and other polar solvents. 1,4'-Bipiperidine dihydrochloride has been studied for its potential applications in the treatment of neurological disorders and as a reagent in chemical reactions.
Uses
Used in Pharmaceutical Industry:
1,4'-Bipiperidine dihydrochloride is used as an intermediate in the synthesis of various drugs, such as antihistamines and antipsychotics, due to its chemical properties and reactivity.
Used in Organic Synthesis:
1,4'-Bipiperidine dihydrochloride is used as a reagent in chemical reactions, contributing to the formation of new compounds and facilitating the synthesis of complex organic molecules.
Used in Neurological Disorders Research:
1,4'-Bipiperidine dihydrochloride is used as a potential therapeutic agent in the treatment of neurological disorders, as it has been studied for its effects on the nervous system.
However, it is important to handle and use 1,4'-Bipiperidine dihydrochloride with caution, as it can be toxic and harmful if ingested, inhaled, or in contact with skin and eyes.
Check Digit Verification of cas no
The CAS Registry Mumber 4876-60-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,8,7 and 6 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 4876-60:
(6*4)+(5*8)+(4*7)+(3*6)+(2*6)+(1*0)=122
122 % 10 = 2
So 4876-60-2 is a valid CAS Registry Number.
4876-60-2Relevant articles and documents
Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation
Munoz, Lenka,Kavanagh, Madeline E.,Phoa, Athena F.,Heng, Benjamin,Dzamko, Nicolas,Chen, Ew-Jun,Doddareddy, Munikumar Reddy,Guillemin, Gilles J.,Kassiou, Michael
, p. 29 - 34 (2015)
LRRK2IN1 is a highly potent inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 = 7.9 nM), an established target for treatment of Parkinson's disease. Two LRRK2IN1 analogues 1 and 2 were synthesised which retained LRRK2 inhibitory activity (1: IC50 = 72 nM; 2: IC50 = 51 nM), were predicted to have improved bioavailability and were efficacious in cell-based models of neuroinflammation. Analogue 1 inhibited IL-6 secretion from LPS-stimulated primary human microglia with EC50 = 4.26 μM. In order to further optimize the molecular properties of LRRK2IN1, a library of truncated analogues was designed based on docking studies. Despite lacking LRRK2 inhibitory activity, these compounds show antineuroinflammatory efficacy at micromolar concentration. The compounds developed were valuable tools in establishing a cell-based assay for assessing anti-neuroinflammatory efficacy of LRRK2 inhibitors. Herein, we present data that IL-1β stimulated U87 glioma cell line is a reliable model for neuroinflammation, as data obtained in this model were consistent with results obtained using primary human microglia and astrocytes.
